Agilent Technologies Inc - Asset Resilience Ratio
Agilent Technologies Inc (A) has an Asset Resilience Ratio of 12.22% as of April 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read A total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Agilent Technologies Inc's Asset Resilience Ratio has changed over time. See A net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Agilent Technologies Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Agilent Technologies Inc (A) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $1.49 Billion | 12.22% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $1.49 Billion | 12.22% |
Asset Resilience Insights
- Moderate Liquidity: Agilent Technologies Inc has 12.22% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Agilent Technologies Inc Industry Peers by Asset Resilience Ratio
Compare Agilent Technologies Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Agilent Technologies Inc (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Agilent Technologies Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-10-31 | 11.22% | $1.33 Billion | $11.85 Billion | -3.55pp |
| 2023-10-31 | 14.77% | $1.59 Billion | $10.76 Billion | +4.77pp |
| 2022-10-31 | 10.00% | $1.05 Billion | $10.53 Billion | -4.71pp |
| 2021-10-31 | 14.71% | $1.57 Billion | $10.71 Billion | -1.90pp |
| 2020-10-31 | 16.61% | $1.60 Billion | $9.63 Billion | +1.99pp |
| 2019-10-31 | 14.62% | $1.38 Billion | $9.45 Billion | -11.69pp |
| 2018-10-31 | 26.31% | $2.25 Billion | $8.54 Billion | -5.47pp |
| 2017-10-31 | 31.78% | $2.68 Billion | $8.43 Billion | +2.50pp |
| 2016-10-31 | 29.28% | $2.29 Billion | $7.82 Billion | +26.05pp |
| 2015-10-31 | 3.24% | $242.00 Million | $7.48 Billion | -- |
| 2014-10-31 | 0.00% | $0.00 | $10.76 Billion | -- |
| 2013-10-31 | 0.00% | $0.00 | $10.69 Billion | -- |
| 2012-10-31 | 0.10% | $11.00 Million | $10.54 Billion | -- |
| 2011-10-31 | 0.00% | $0.00 | $9.06 Billion | -- |
| 2010-10-31 | 15.99% | $1.55 Billion | $9.70 Billion | +15.80pp |
| 2009-10-31 | 0.18% | $14.00 Million | $7.61 Billion | -0.14pp |
| 2008-10-31 | 0.32% | $24.00 Million | $7.44 Billion | -0.05pp |
| 2005-10-31 | 0.37% | $25.00 Million | $6.75 Billion | +0.36pp |
| 2002-10-31 | 0.01% | $1.00 Million | $8.20 Billion | -2.96pp |
| 2001-10-31 | 2.97% | $237.00 Million | $7.99 Billion | -- |
About Agilent Technologies Inc
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrome… Read more